Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,501,909
  • Shares Outstanding, K 188,255
  • Annual Sales, $ 42,730 K
  • Annual Income, $ -204,380 K
  • EBIT $ -215 M
  • EBITDA $ -207 M
  • 60-Month Beta -1.77
  • Price/Sales 57.81
  • Price/Cash Flow N/A
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 107.50% (-4.98%)
  • Historical Volatility 53.66%
  • IV Percentile 65%
  • IV Rank 33.04%
  • IV High 199.53% on 11/05/25
  • IV Low 62.09% on 08/21/25
  • Expected Move (DTE 10) 2.00 (14.52%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 802
  • Volume Avg (30-Day) 1,714
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 49,901
  • Open Int (30-Day) 42,967
  • Expected Range 11.76 to 15.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.34
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -17.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.51 +10.15%
on 02/12/26
15.47 -10.92%
on 02/26/26
+0.19 (+1.40%)
since 02/10/26
3-Month
12.51 +10.15%
on 02/12/26
20.00 -31.10%
on 12/11/25
-6.45 (-31.88%)
since 12/10/25
52-Week
5.28 +160.98%
on 04/09/25
21.73 -36.59%
on 12/09/25
+4.39 (+46.75%)
since 03/10/25

Most Recent Stories

More News
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference...

WVE : 13.77 (+3.61%)
Wave Life Sciences: Q4 Earnings Snapshot

Wave Life Sciences: Q4 Earnings Snapshot

WVE : 13.77 (+3.61%)
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while...

WVE : 13.77 (+3.61%)
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 13.77 (+3.61%)
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 13.77 (+3.61%)
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies...

WVE : 13.77 (+3.61%)
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007...

WVE : 13.77 (+3.61%)
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 13.77 (+3.61%)
Golden Cross Alert: 3 Stocks With Major Upside Potential

Three stocks flashing a golden cross—Sun Communities, Darling Ingredients, and Wave Life Sciences—may offer strong upside potential heading into 2026

DAR : 52.58 (+1.27%)
SUI : 136.68 (+0.92%)
NVO : 38.69 (-2.74%)
WVE : 13.77 (+3.61%)
LLY : 1,000.91 (-0.74%)
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 13.77 (+3.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 14.50
2nd Resistance Point 14.00
1st Resistance Point 13.65
Last Price 13.77
1st Support Level 12.80
2nd Support Level 12.30
3rd Support Level 11.95

See More

52-Week High 21.73
Fibonacci 61.8% 15.45
Last Price 13.77
Fibonacci 50% 13.51
Fibonacci 38.2% 11.56
52-Week Low 5.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar